Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis
May 11 2016 - 7:05AM
myVectraTM Enables Secure Access to Vectra® DA
Test Results
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that it has launched a new
web-based portal called myVectra for patients with rheumatoid
arthritis (RA). myVectra provides patients with easy access
to their Vectra DA test results and test history, which can help
them to prepare for visits with their rheumatologist. Patients will
have access to their results in the portal seven days after they
are sent to their rheumatologist (approximately two weeks after
their blood is drawn for the Vectra DA test). The new portal is
available at: my.vectrada.com
Vectra DA is the first and only multi-biomarker
blood test to measure disease activity in patients with RA.
Tracking and knowing their Vectra DA scores allows patients to be
better informed about their disease activity and changes over time,
and to be prepared to discuss the best course of disease management
with their rheumatologist. myVectra in conjunction with the
MyRA® mobile application (trackmyra.com) allows
patients using an iPhone®, iPad®,
or Android™ smartphone to track how they are feeling and remind
them of that information for their next visit with their
rheumatologist. myVectra and MyRA give patients important
information to monitor their disease activity and health
journey.
"We are committed to improving the lives of
patients with rheumatoid arthritis. When patients access
their Vectra DA test results through myVectra, they will gain a
better understanding of their disease activity and become active
participants in their care," said Bernie Tobin, president,
Crescendo Bioscience. “This information improves patient
engagement, empowerment and communications with their
rheumatologist."
About Vectra® DA Vectra DA is
the only multi-biomarker blood test for rheumatoid arthritis (RA)
disease activity that integrates the concentrations of 12 serum
proteins associated with RA disease activity into a single
objective score, on a scale of 1 to 100, to help physicians make
more informed treatment decisions. Vectra DA testing is performed
at the Crescendo Bioscience state-of-the-art CLIA (Clinical
Laboratory Improvement Amendments) facility. Test results are
reported to the physician 5 to 7 days from shipping of the specimen
to Crescendo Bioscience. Physicians can receive test results via
standard mail, by fax or via the private web portal, VectraView.
For more information on Vectra DA, please visit,
www.Vectra-DA.com.
About Crescendo
BioscienceCrescendo Bioscience, a wholly-owned subsidiary
of Myriad Genetics, Inc., is a molecular diagnostics company
dedicated to developing and commercializing quantitative blood
tests for rheumatoid arthritis (RA) and other autoimmune diseases,
located in South San Francisco, California. Crescendo
Bioscience develops quantitative, objective, reproducible blood
tests to provide rheumatologists with deeper clinical insight to
help enable more effective management of patients with autoimmune
and inflammatory diseases. For more information, please visit
the company website at: www.CrescendoBio.com.
About Myriad GeneticsMyriad
Genetics Inc., is a leading personalized medicine company dedicated
to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra, myVectra, MyRA and Prolaris
are trademarks or registered trademarks of Myriad Genetics, Inc. or
its wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
iPhone and iPad are registered trademarks of Apple
Inc. Android is a trademark of Google Inc.
Safe Harbor StatementThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to the timing and utility of the
my.vectrada.com website to provide patients with fast and easy
access to their Vectra DA test results; the ability of the Vectra
DA test to provide a better understanding of their disease activity
and improve care; and the Company’s strategic directives under the
caption “About Myriad Genetics.” These “forward-looking statements”
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing product portfolio to our
new tests; risks related to changes in the governmental or private
insurers’ reimbursement levels for our tests or our ability to
obtain reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services tests and any future tests are terminated or cannot be
maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks
related to public concern over our genetic testing in general or
our tests in particular; risks related to regulatory requirements
or enforcement in the United States and foreign countries and
changes in the structure of the healthcare system or healthcare
payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies
or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of a healthcare clinic in
Germany; risks related to our projections about the potential
market opportunity for our products; the risk that we or our
licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form
10-K for the fiscal year ended June 30, 2015, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024